EP3968963A4 - Formulations d'imatinib, leur fabrication et leurs utilisations - Google Patents

Formulations d'imatinib, leur fabrication et leurs utilisations Download PDF

Info

Publication number
EP3968963A4
EP3968963A4 EP20806383.4A EP20806383A EP3968963A4 EP 3968963 A4 EP3968963 A4 EP 3968963A4 EP 20806383 A EP20806383 A EP 20806383A EP 3968963 A4 EP3968963 A4 EP 3968963A4
Authority
EP
European Patent Office
Prior art keywords
manufacture
imatinib formulations
imatinib
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20806383.4A
Other languages
German (de)
English (en)
Other versions
EP3968963A1 (fr
Inventor
Ben DAKE
Ralph Niven
Andrew D. LEVIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aerovate Therapeutics Inc
Original Assignee
Aerovate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerovate Therapeutics Inc filed Critical Aerovate Therapeutics Inc
Publication of EP3968963A1 publication Critical patent/EP3968963A1/fr
Publication of EP3968963A4 publication Critical patent/EP3968963A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP20806383.4A 2019-05-16 2020-05-14 Formulations d'imatinib, leur fabrication et leurs utilisations Pending EP3968963A4 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962849058P 2019-05-16 2019-05-16
US201962849054P 2019-05-16 2019-05-16
US201962849059P 2019-05-16 2019-05-16
US201962849056P 2019-05-16 2019-05-16
US201962877575P 2019-07-23 2019-07-23
US201962942408P 2019-12-02 2019-12-02
US202062958481P 2020-01-08 2020-01-08
US202062984037P 2020-03-02 2020-03-02
PCT/US2020/032872 WO2020232236A1 (fr) 2019-05-16 2020-05-14 Formulations d'imatinib, leur fabrication et leurs utilisations

Publications (2)

Publication Number Publication Date
EP3968963A1 EP3968963A1 (fr) 2022-03-23
EP3968963A4 true EP3968963A4 (fr) 2023-02-01

Family

ID=73228465

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20806383.4A Pending EP3968963A4 (fr) 2019-05-16 2020-05-14 Formulations d'imatinib, leur fabrication et leurs utilisations
EP20806763.7A Pending EP3969111A4 (fr) 2019-05-16 2020-05-14 Formulations inhalables pour l'inhibition de kinases

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20806763.7A Pending EP3969111A4 (fr) 2019-05-16 2020-05-14 Formulations inhalables pour l'inhibition de kinases

Country Status (14)

Country Link
US (13) US20200360277A1 (fr)
EP (2) EP3968963A4 (fr)
JP (1) JP2022532431A (fr)
KR (1) KR20220050839A (fr)
CN (1) CN114514016A (fr)
AU (1) AU2020274521A1 (fr)
BR (1) BR112021023014A2 (fr)
CA (1) CA3140641A1 (fr)
IL (1) IL288111A (fr)
JO (1) JOP20210305A1 (fr)
MX (1) MX2021014029A (fr)
SG (1) SG11202112719XA (fr)
WO (2) WO2020232238A1 (fr)
ZA (1) ZA202109070B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3172586A1 (fr) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Composes d'imatinib en aerosol et utilisations connexes
CN114514016A (zh) * 2019-05-16 2022-05-17 埃渃维特治疗学公司 伊马替尼调配物、制造和其用途
KR20230131179A (ko) * 2020-11-17 2023-09-12 유나이티드 쎄러퓨틱스 코포레이션 폐 고혈압 분야를 위한 흡입형 이마티닙
WO2022109458A1 (fr) * 2020-11-23 2022-05-27 Aerovate Therapeutics, Inc. Formulations d'imatinib, fabrication et utilisations de celles-ci
JP2024502990A (ja) * 2021-01-06 2024-01-24 インカーダ セラピューティクス， インコーポレイテッド 吸入可能なイマチニブ製剤
KR102634754B1 (ko) * 2021-07-07 2024-02-08 애니머스큐어 주식회사 이마티닙을 포함하는 근육 질환의 예방 또는 치료용 조성물
WO2023147868A1 (fr) * 2022-02-04 2023-08-10 Justus-Liebig-Universität Giessen Imatinib inhalé pour le traitement de l'hypertension pulmonaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1988089A1 (fr) * 2006-10-26 2008-11-05 Sicor, Inc. Base d'imatinib, et mesylate d'imatinib et son procédé de préparation
EP2582689A1 (fr) * 2010-06-18 2013-04-24 KRKA, D.D., Novo Mesto Nouvelle forme polymorphique d'imatinib base et préparation de ses sels

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO1996025918A1 (fr) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols contenant des dispersions de nanoparticules
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
GB2398565A (en) 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
US20040204439A1 (en) 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP2260849A1 (fr) 2004-01-21 2010-12-15 Emory University Compositions et procédés à utiliser pour les inhibiteurs de tyrosine kinase pour traiter les infections pathogènes
EP1833815B1 (fr) 2004-12-30 2010-09-15 Instytut Farmaceutyczny Procede de preparation d'une base d'imatinibe
US7507821B2 (en) 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
EP1695728A1 (fr) 2005-02-23 2006-08-30 Activaero GmbH Composant pour un dispositif d'inhalation, le dispositif d'inhalation avec ce composant et une méthode de contrôle pour un tel composant
EP1700614B1 (fr) 2005-03-08 2013-05-08 Activaero GmbH Dispositif d'inhalation
JP2008542397A (ja) * 2005-06-03 2008-11-27 エラン ファーマ インターナショナル リミテッド ナノ粒子メシル酸イマチニブ製剤
ES2290827T3 (es) 2005-07-06 2008-02-16 Activaero Gmbh Valvula regulable y dispositivo para inhalar.
EP2111863B1 (fr) 2005-10-26 2012-03-28 Asahi Kasei Pharma Corporation Combinaison du fasudil et bosentan pour le traitement de l'hypertension artérielle pulmonaire
MXPA06007070A (es) 2006-03-24 2007-09-24 Univ Kyushu Compuestos organicos.
US20060223817A1 (en) 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
US20080181958A1 (en) 2006-06-19 2008-07-31 Rothrock Ginger D Nanoparticle fabrication methods, systems, and materials
EP2076507A2 (fr) 2006-10-26 2009-07-08 Sicor, Inc. Imatinib base et mésylate d'imatinib et procédés pour la préparation de ceux-ci
US20130177598A1 (en) * 2007-02-27 2013-07-11 The University Of North Carolina At Chapel Hill Discrete size and shape specific pharmaceutical organic nanoparticles
WO2008136010A1 (fr) 2007-05-07 2008-11-13 Natco Pharma Limited Procédé de préparation de l'imatinib base hautement pure
ES2526211T3 (es) 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
ES2398921T3 (es) 2007-08-02 2013-03-22 Activaero Gmbh Dispositivo y sistema para dirigir partículas aerosolizadas a un área específica de los pulmones
EP2033674A1 (fr) 2007-09-06 2009-03-11 Activaero GmbH Appareil d'inhalation
RU2011109078A (ru) 2008-08-13 2012-09-20 Новартис АГ (CH) Лечение легочной артериальной гипертензии
US8834848B2 (en) 2009-02-04 2014-09-16 Activaero Gmbh Research & Development Flow and volume regulated inhalation for treatment of severe oral corticosteroid-dependent asthma
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
WO2011039782A1 (fr) 2009-09-29 2011-04-07 Ind-Swift Laboratories Limited Procédés de préparation d'imatinib et de ses sels pharmaceutiquement acceptables
WO2011038901A1 (fr) 2009-09-29 2011-04-07 Activaero Gmbh Procédé amélioré pour le traitement de patients atteints de la mucoviscidose
EP2509973A1 (fr) 2009-12-10 2012-10-17 Arch Pharmalabs Limited Procédé de préparation d'imatinib et de ses sels
WO2011095835A1 (fr) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Imatinib de grande pureté ou un sel pharmaceutiquement acceptable de celui-ci
WO2011100282A2 (fr) 2010-02-09 2011-08-18 Dr. Reddy's Laboratories Ltd. Polymorphes de mésylate d'imatinib
EP2547671A1 (fr) 2010-03-15 2013-01-23 Natco Pharma Limited Procédé de préparation d'une base imatinib cristalline très pure
TR201007005A2 (tr) 2010-08-23 2011-09-21 Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. İmatinib baz üretim yöntemi
WO2012090221A1 (fr) 2010-12-29 2012-07-05 Cadila Healthcare Limited Nouveaux sels d'imatinib
DK2670242T3 (da) 2011-01-31 2022-05-02 Avalyn Pharma Inc Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP2965748A1 (fr) 2011-04-26 2016-01-13 Vectura GmbH Administration d'iloprost en tant que bolus aérosol
KR101903028B1 (ko) 2012-03-09 2018-10-02 벡투라 게엠베하 흡입 장치용 혼합 채널 및 흡입 장치
CN103570676B (zh) * 2012-08-04 2016-03-16 正大天晴药业集团股份有限公司 甲磺酸伊马替尼α结晶的制备及其药物组合物
JP2015529683A (ja) * 2012-09-17 2015-10-08 バインド セラピューティックス インコーポレイテッド 治療剤を含む治療用ナノ粒子とその製造方法および使用方法
DK2724741T3 (en) 2012-10-26 2017-09-18 Vectura Gmbh Inhalation device for use in aerosol treatment
EP2914244B1 (fr) 2012-10-31 2024-01-03 Vectura GmbH Administration d'iloprost en aérosol
CA2897651C (fr) 2013-01-10 2021-09-21 Pulmokine, Inc. Inhibiteurs de kinase non selectifs
AU2014205481A1 (en) * 2013-01-10 2015-08-27 Gilead Sciences, Inc. Therapeutic indications of kinase inhibitors
CA3172586A1 (fr) * 2013-07-31 2015-02-05 Avalyn Pharma Inc. Composes d'imatinib en aerosol et utilisations connexes
TR201808138T4 (tr) 2013-08-16 2018-07-23 Vectura Gmbh Bir inhalasyon cihazı için dozlama sistemi.
CA2926793C (fr) 2013-10-11 2022-11-22 Lawrence S. ZISMAN Formulations a sechage par pulverisation pour le traitement de l'hypertension arterielle pulmonaire
EP3091976A4 (fr) 2014-01-10 2017-10-11 Genoa Pharmaceuticals Inc. Composés analogues de pyridone et de pirfénidone en aérosol, et leurs utilisations
CN103910711A (zh) * 2014-03-24 2014-07-09 福建天泉药业股份有限公司 一种伊马替尼游离碱晶型及其制备方法
WO2015188243A1 (fr) * 2014-06-10 2015-12-17 Cristália Produtos Químicos Farmacêuticos Ltda Procédé de préparation d'imatinib et de mésylate d'imatinib sous forme α2 non aciculaire
KR20170093120A (ko) 2014-10-10 2017-08-14 아블린쓰 엔.브이. Rsv 감염의 치료 방법
WO2017042341A1 (fr) 2015-09-09 2017-03-16 Vectura Limited Procédé de broyage à jet
WO2017042696A1 (fr) 2015-09-09 2017-03-16 Novartis Ag Administration ciblée de formulations séchées par pulvérisation aux poumons
CN110730819A (zh) 2016-10-26 2020-01-24 索尼克马斯特有限公司 肌肉谱系细胞的改善产生及其治疗用途
RU2766163C2 (ru) 2017-09-19 2022-02-08 Эвапко, Инк. Теплообменное устройство воздушного охлаждения с интегрированной и механизированной системой предварительного охлаждения воздуха
AU2019324188A1 (en) 2018-08-22 2021-04-01 Avalyn Pharma Inc. Specially formulated compositions of inhaled nintedanib and nintedanib salts
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
CN114514016A (zh) * 2019-05-16 2022-05-17 埃渃维特治疗学公司 伊马替尼调配物、制造和其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1988089A1 (fr) * 2006-10-26 2008-11-05 Sicor, Inc. Base d'imatinib, et mesylate d'imatinib et son procédé de préparation
EP2582689A1 (fr) * 2010-06-18 2013-04-24 KRKA, D.D., Novo Mesto Nouvelle forme polymorphique d'imatinib base et préparation de ses sels

Also Published As

Publication number Publication date
US20240108622A1 (en) 2024-04-04
IL288111A (en) 2022-01-01
US20230086230A1 (en) 2023-03-23
US20200360279A1 (en) 2020-11-19
WO2020232238A1 (fr) 2020-11-19
US20240041879A1 (en) 2024-02-08
WO2020232236A1 (fr) 2020-11-19
KR20220050839A (ko) 2022-04-25
EP3969111A1 (fr) 2022-03-23
AU2020274521A1 (en) 2021-12-16
US20200360275A1 (en) 2020-11-19
CA3140641A1 (fr) 2020-11-19
MX2021014029A (es) 2022-02-21
US20230056721A1 (en) 2023-02-23
ZA202109070B (en) 2023-01-25
US20220218706A1 (en) 2022-07-14
US20200360277A1 (en) 2020-11-19
US11229650B2 (en) 2022-01-25
US11413289B2 (en) 2022-08-16
US20200360377A1 (en) 2020-11-19
US20200360477A1 (en) 2020-11-19
US20200360276A1 (en) 2020-11-19
SG11202112719XA (en) 2021-12-30
US11813263B2 (en) 2023-11-14
EP3968963A1 (fr) 2022-03-23
BR112021023014A2 (pt) 2022-02-08
JP2022532431A (ja) 2022-07-14
CN114514016A (zh) 2022-05-17
US20200360376A1 (en) 2020-11-19
US11806349B2 (en) 2023-11-07
JOP20210305A1 (ar) 2023-01-30
US20220184080A1 (en) 2022-06-16
EP3969111A4 (fr) 2023-08-16
US11298355B2 (en) 2022-04-12

Similar Documents

Publication Publication Date Title
EP3968963A4 (fr) Formulations d'imatinib, leur fabrication et leurs utilisations
EP3917526A4 (fr) Composés et leurs utilisations
EP3917934A4 (fr) Composés et leurs utilisations
EP4076448A4 (fr) Oxadiazoles fluoroalkylés et leurs utilisations
EP3917529A4 (fr) Composés et leurs utilisations
EP3917517A4 (fr) Composés et leurs utilisations
EP3990618A4 (fr) Macrophages activés par hdac6, compositions et utilisations associées
EP3917527A4 (fr) Composés et leurs utilisations
EP3654982A4 (fr) Composés de 1,8-naphthyridinone et leurs utilisations
EP3980009A4 (fr) Formulations à libération modifiée et utilisations associées
EP3941908A4 (fr) Composés et leurs utilisations
EP3551619A4 (fr) Compositions comprenant des promédicaments méthylphénidates, procédés de fabrication et d'utilisation de ces compositions
EP3691629A4 (fr) Formulations nutriment-spores et leurs utilisations
EP4034535A4 (fr) Composés d'aza-quinoléine et leurs utilisations
EP3911324A4 (fr) Composés de 1,8-naphthyridinone et leurs utilisations
EP3911322A4 (fr) Composés et leurs utilisations
EP3947365A4 (fr) Composés n-hétéroaryle substitués et leurs utilisations
EP3854242A4 (fr) Chemise réversible
EP4007590A4 (fr) Formulations comprenant du dihydrohonokiol
EP4019536A4 (fr) Immunocytokine, sa préparation et ses utilisations
EP3980008A4 (fr) Formulations à libération modifiée et utilisations associées
EP3932909A4 (fr) Composé de benzoindazolone et intermédiaire de celui-ci
EP3914593A4 (fr) Composés et leurs utilisations
EP4013441A4 (fr) Formulations de larazotide
EP3999089A4 (fr) Formulations phytogènes anticoccidiennes

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230105

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/19 20060101ALI20221223BHEP

Ipc: A61K 38/18 20060101ALI20221223BHEP

Ipc: A61K 31/501 20060101ALI20221223BHEP

Ipc: A61K 9/00 20060101ALI20221223BHEP

Ipc: A61P 11/00 20060101ALI20221223BHEP

Ipc: A61K 31/506 20060101ALI20221223BHEP

Ipc: A61P 9/12 20060101ALI20221223BHEP

Ipc: A61K 47/26 20060101ALI20221223BHEP

Ipc: A61K 47/24 20060101ALI20221223BHEP

Ipc: A61K 9/14 20060101AFI20221223BHEP